- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 9015-68-3] L-Asparaginase
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-P1923 |
| Brand: | MCE |
| CAS: | 9015-68-3 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | - |
| Molecular Formula | Unspecified |
| SMILES | - |
4 Publications Citing Use of MCE
Summary
L-Asparaginase (L-ASNase) is a deamidating enzyme that catalyses the hydrolysis of L-asparagine and L-glutamine, and can be used for the research of acute lymphoblastic leukemia. L-Asparaginase depletes L-asparagine from plasma resulting in inhibition of RNA and DNA synthesis with the subsequent blastic cell apoptosis [1] .
In Vitro
L-Asparaginase has a cytotoxic effect on AML blasts and LSC subpopulations
[1]
.
L-Asparaginase is effective on both CD34
+
CD38
+
and CD34
+
CD38
+
LSC fractions, MSC and monocytes/macrophages partially counteracted the effect
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT00526305 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
January 2000 | Phase 4 |
| NCT01225874 | Children´s Oncology Group|National Cancer Institute (NCI) |
Leukemia
|
December 1999 | Not Applicable |
| NCT01518517 | ERYtech Pharma |
Acute Lymphoblastic Leukemia, in Relapse
|
December 2009 | Phase 2|Phase 3 |
| NCT01953770 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology |
Childhood Acute Lymphoblastic Leukemia
|
February 2008 | Not Applicable |
| NCT02894645 | National University Hospital, Singapore |
Acute Lymphoblastic Leukemia (ALL)
|
October 2008 | Phase 4 |
| NCT00098839 | Children´s Oncology Group|National Cancer Institute (NCI) |
Recurrent Childhood Acute Lymphoblastic Leukemia
|
February 2005 | Phase 1|Phase 2 |
| NCT01313078 | National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) |
Ovarian Neoplasms|Fallopian Tube Neoplasms|Primary Peritoneal Neoplasms
|
January 2010 | Phase 2 |
| NCT03286634 | National Hospital Organization Nagoya Medical Center |
Down Syndrome|Acute Lymphoblastic Leukemia|Childhood Cancer
|
April 18, 2017 | Phase 2 |
| NCT00873093 | National Cancer Institute (NCI) |
B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Lymphoblastic Lymphoma|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia
|
March 2009 | Phase 2 |
| NCT00187057 | St. Jude Children´s Research Hospital|Children´s Hospital of Philadelphia|National Cancer Institute (NCI) |
Ataxia-Telangiectasia
|
September 2002 | Not Applicable |
| NCT04440267 | wang, jianxiang|Institute of Hematology & Blood Diseases Hospital |
Acute Leukemia of Ambiguous Lineage
|
June 20, 2020 | Phase 2 |
| NCT02197650 | ERYtech Pharma |
Acute Lymphoblastic Leukemia
|
||
| NCT03071822 | The University of Hong Kong |
Peripheral T Cell Lymphoma
|
February 24, 2017 | Phase 4 |
| NCT00526175 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
June 2001 | Phase 4 |
| NCT02544425 | Samsung Medical Center |
Extranodal NK-T-Cell Lymphoma
|
February 21, 2016 | Phase 2 |
| NCT00187122 | St. Jude Children´s Research Hospital |
Lymphoblastic Lymphoma
|
March 1993 | Not Applicable |
| NCT03623087 | The University of Hong Kong |
Non-Hodgkin´s Lymphoma, Relapsed|Non-Hodgkin T-cell Lymphoma|Natural Killer+T-Cell Lymphoma, Nasal and Nasal-Type
|
July 1, 2017 | Phase 3 |
| NCT03150693 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) |
B Acute Lymphoblastic Leukemia
|
June 1, 2017 | Phase 3 |
| NCT04230330 | National Cancer Centre, Singapore|Bristol-Myers Squibb |
NK+T Cell Lymphoma
|
December 12, 2019 | Phase 1 |
| NCT00590915 | Phoenix Children´s Hospital|Fisher Bioservices|Jazz Pharmaceuticals |
Leukemia, Acute Lymphoblastic|Acute Lymphoid Leukemia
|
||
| NCT01910428 | ERYtech Pharma |
Acute Lymphoblastic Leukemia|Lymphoblastic Lymphoma
|
October 2013 | Phase 1 |
| NCT00526409 | PETHEMA Foundation |
Acute Lymphoblastic Leukemia
|
June 2005 | Phase 4 |
| NCT00136435 | Dana-Farber Cancer Institute|Brigham and Women´s Hospital|Massachusetts General Hospital|Queen Elizabeth II Health Sciences Centre |
Acute Lymphoblastic Leukemia
|
June 2002 | Phase 2 |
| NCT02036489 | PETHEMA Foundation |
Acute Lymphobkastic Leukemia
|
January 2008 | Phase 4 |
| NCT01358253 | Ruijin Hospital |
Acute Lymphoblastic Leukemia
|
December 2010 | Phase 4 |
| NCT03079544 | Rong Tao|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
Extranodal NK-T-Cell Lymphoma, Nasal Type
|
March 8, 2017 | |
| NCT00131053 | Japan Adult Leukemia Study Group |
Lymphoblastic Leukemia, Acute
|
September 2002 | Phase 2 |
| NCT00176462 | Rutgers, The State University of New Jersey|National Cancer Institute (NCI) |
Acute Lymphocytic Leukemia
|
February 2001 | Phase 2 |
| NCT00854425 | Fudan University |
Lymphoma
|
June 2008 | Phase 2 |
| NCT00131027 | Japan Adult Leukemia Study Group |
Lymphoblastic Leukemia, Acute
|
September 2002 | Phase 3 |
| NCT02419755 | St. Jude Children´s Research Hospital |
Mixed Lineage Acute Leukemia|Acute Myeloid Leukemia|Acute Lymphoid Leukemia
|
April 14, 2015 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Sealed storage, away from moisture and light
| Powder | -80°C | 2 years |
|---|---|---|
| -20°C | 1 year |
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
0.1 M HCL : 50 mg/mL (ultrasonic and adjust pH to 3 with HCl)
H 2 O : 1 mg/mL (ultrasonic and warming and heat to 50°C)
-
1.
Add each solvent one by one: PBS
Solubility: 25 mg/mL (Infinity mM); Clear solution; Need ultrasonic
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.